.The Invitae Spinal Muscular Atrophy test analyzes SMN1, which is known to cause spinal muscular atrophy (SMA), and SMN2, which can modify the phenotype in individuals with SMN1-related SMA.
*Invitae Comprehensive Neuromuscular Disorders Panel available as automatic reflex upon negative results found on the Invitae Spinal Muscular Atrophy Panel.
.The Invitae Spinal Muscular Atrophy STAT test analyzes the copy number of SMN1, which is known to cause spinal muscular atrophy (SMA). SMN2 copy number, which can modify disease severity in individuals with SMN1-related SMA, is reported for individuals with a homozygous deletion of SMN1.
If you don’t find answers with your initial order,
Spinal Muscular Atrophy (SMA/AME) genetic testing program includes one re-requisition within 90 days to genes within the original clinical area.
Simply log into your account, navigate to the order, and click "Add rerequisition”
If a positive result is identified, testing for your patient’s family members is available.
Simply follow the ordering instructions, selecting only the gene(s) you are interested in testing for the family member. The partner code will automatically be added with the order.
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. For more information, please visit www.roche.com.